Logo image of TSHA

TAYSHA GENE THERAPIES INC (TSHA) Stock Fundamental Analysis

NASDAQ:TSHA - Nasdaq - US8776191061 - Common Stock - Currency: USD

2.72  -0.09 (-3.2%)

After market: 2.77 +0.05 (+1.84%)

Fundamental Rating

2

Taking everything into account, TSHA scores 2 out of 10 in our fundamental rating. TSHA was compared to 551 industry peers in the Biotechnology industry. Both the profitability and financial health of TSHA have multiple concerns. TSHA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year TSHA has reported negative net income.
TSHA had a negative operating cash flow in the past year.
In the past 5 years TSHA always reported negative net income.
TSHA had a negative operating cash flow in each of the past 5 years.
TSHA Yearly Net Income VS EBIT VS OCF VS FCFTSHA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

With a Return On Assets value of -62.71%, TSHA is not doing good in the industry: 60.25% of the companies in the same industry are doing better.
TSHA has a Return On Equity of -157.59%. This is in the lower half of the industry: TSHA underperforms 63.52% of its industry peers.
Industry RankSector Rank
ROA -62.71%
ROE -157.59%
ROIC N/A
ROA(3y)-83.9%
ROA(5y)-71.29%
ROE(3y)-6239.76%
ROE(5y)-3785.22%
ROIC(3y)N/A
ROIC(5y)N/A
TSHA Yearly ROA, ROE, ROICTSHA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TSHA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TSHA Yearly Profit, Operating, Gross MarginsTSHA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -2K -4K -6K

More info and screens

3

2. Health

2.1 Basic Checks

TSHA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TSHA has more shares outstanding
TSHA has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, TSHA has a worse debt to assets ratio.
TSHA Yearly Shares OutstandingTSHA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
TSHA Yearly Total Debt VS Total AssetsTSHA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

TSHA has an Altman-Z score of -2.47. This is a bad value and indicates that TSHA is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -2.47, TSHA is in line with its industry, outperforming 50.45% of the companies in the same industry.
TSHA has a Debt/Equity ratio of 0.77. This is a neutral value indicating TSHA is somewhat dependend on debt financing.
TSHA has a Debt to Equity ratio of 0.77. This is in the lower half of the industry: TSHA underperforms 75.68% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.77
Debt/FCF N/A
Altman-Z -2.47
ROIC/WACCN/A
WACC11.37%
TSHA Yearly LT Debt VS Equity VS FCFTSHA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

TSHA has a Current Ratio of 5.35. This indicates that TSHA is financially healthy and has no problem in meeting its short term obligations.
TSHA has a Current ratio (5.35) which is in line with its industry peers.
A Quick Ratio of 5.35 indicates that TSHA has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 5.35, TSHA is in line with its industry, outperforming 57.53% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.35
Quick Ratio 5.35
TSHA Yearly Current Assets VS Current LiabilitesTSHA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for TSHA have decreased strongly by -209.68% in the last year.
The Revenue for TSHA has decreased by -49.00% in the past year. This is quite bad
EPS 1Y (TTM)-209.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
Revenue 1Y (TTM)-49%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-32.51%

3.2 Future

TSHA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.27% yearly.
TSHA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 124.96% yearly.
EPS Next Y6.74%
EPS Next 2Y-4.67%
EPS Next 3Y-0.19%
EPS Next 5Y24.27%
Revenue Next Year-13.49%
Revenue Next 2Y-25.97%
Revenue Next 3Y21.25%
Revenue Next 5Y124.96%

3.3 Evolution

TSHA Yearly Revenue VS EstimatesTSHA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
TSHA Yearly EPS VS EstimatesTSHA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TSHA. In the last year negative earnings were reported.
Also next year TSHA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TSHA Price Earnings VS Forward Price EarningsTSHA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TSHA Per share dataTSHA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-4.67%
EPS Next 3Y-0.19%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TSHA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TAYSHA GENE THERAPIES INC

NASDAQ:TSHA (8/8/2025, 8:09:50 PM)

After market: 2.77 +0.05 (+1.84%)

2.72

-0.09 (-3.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-15 2025-05-15/bmo
Earnings (Next)08-12 2025-08-12/bmo
Inst Owners67.37%
Inst Owner Change0.27%
Ins Owners1.22%
Ins Owner Change0.81%
Market Cap685.22M
Analysts84.44
Price Target8.2 (201.47%)
Short Float %19.86%
Short Ratio11.34
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.29%
Min EPS beat(2)15.26%
Max EPS beat(2)17.32%
EPS beat(4)3
Avg EPS beat(4)18.28%
Min EPS beat(4)-5.87%
Max EPS beat(4)46.41%
EPS beat(8)6
Avg EPS beat(8)126.24%
EPS beat(12)9
Avg EPS beat(12)89.36%
EPS beat(16)9
Avg EPS beat(16)62.43%
Revenue beat(2)1
Avg Revenue beat(2)19.16%
Min Revenue beat(2)-14.14%
Max Revenue beat(2)52.45%
Revenue beat(4)2
Avg Revenue beat(4)-3.6%
Min Revenue beat(4)-59.07%
Max Revenue beat(4)52.45%
Revenue beat(8)6
Avg Revenue beat(8)24.66%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.26%
PT rev (3m)19.14%
EPS NQ rev (1m)2.29%
EPS NQ rev (3m)8.5%
EPS NY rev (1m)0%
EPS NY rev (3m)10.88%
Revenue NQ rev (1m)-9.11%
Revenue NQ rev (3m)-19.36%
Revenue NY rev (1m)0%
Revenue NY rev (3m)6.46%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 94.85
P/FCF N/A
P/OCF N/A
P/B 12.45
P/tB 12.45
EV/EBITDA N/A
EPS(TTM)-0.34
EYN/A
EPS(NY)-0.39
Fwd EYN/A
FCF(TTM)-0.33
FCFYN/A
OCF(TTM)-0.33
OCFYN/A
SpS0.03
BVpS0.22
TBVpS0.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -62.71%
ROE -157.59%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-83.9%
ROA(5y)-71.29%
ROE(3y)-6239.76%
ROE(5y)-3785.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0.77
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 50.87%
Cap/Sales 8.47%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.35
Quick Ratio 5.35
Altman-Z -2.47
F-Score3
WACC11.37%
ROIC/WACCN/A
Cap/Depr(3y)691.55%
Cap/Depr(5y)1199.42%
Cap/Sales(3y)284.78%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-209.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
EPS Next Y6.74%
EPS Next 2Y-4.67%
EPS Next 3Y-0.19%
EPS Next 5Y24.27%
Revenue 1Y (TTM)-49%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-32.51%
Revenue Next Year-13.49%
Revenue Next 2Y-25.97%
Revenue Next 3Y21.25%
Revenue Next 5Y124.96%
EBIT growth 1Y-5.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-4.5%
EBIT Next 3Y42.37%
EBIT Next 5YN/A
FCF growth 1Y-0.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-23.37%
OCF growth 3YN/A
OCF growth 5YN/A